Download PDF
Thromb Haemost 1985; 54(03): 709-712
DOI: 10.1055/s-0038-1660103
Original Article
Schattauer GmbH Stuttgart

The Dilute Phospholipid APTT: A Sensitive Assay for Verification of Lupus Anticoagulants

Barbara M Alving
The Departments of Hematology and Membrane Biochemistry, Walter Reed Army Institute of Research and the Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, D. C., USA
,
Phillip E Baldwin
The Departments of Hematology and Membrane Biochemistry, Walter Reed Army Institute of Research and the Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, D. C., USA
,
Roberta L Richards
The Departments of Hematology and Membrane Biochemistry, Walter Reed Army Institute of Research and the Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, D. C., USA
,
Beverly J Jackson
The Departments of Hematology and Membrane Biochemistry, Walter Reed Army Institute of Research and the Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, D. C., USA
› Author Affiliations
Further Information

Publication History

Received 19 March 1985

Accepted 29 August 1985

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A simple sensitive method for verification of lupus anticoagulants utilizing dilution of phospholipid in the activated partial thromboplastin time (APTT) system is described. Patient plasma, mixed with an equal volume of normal plasma, is activated with micronized silica. To this mixture are added different dilutions of Thrombofax® and then calcium chloride. Clotting times are plotted linearly against the logarithm of the phospholipid dilutions and slopes are calculated by regression analysis. In this assay the mean negative slope of 19 plasmas that contained antiphospholipid activity was five times greater than those of normal plasma or those obtained from patients having single or multiple coagulation factor deficiencies such as those induced by warfarin. The assay can be modified to test heparinized plasmas. Thus, it is a sensitive means by which to verify the presence of lupus anticoagulants in patients who have congenital or acquired factor deficiencies or who are receiving anticoagulant therapy.

Keywords

Lupus anticoagulant - Liposomes - Anti-phospholipid antibodies
 

  • References

  • 1 Thiagarajan p, Shapiro SS, De Marco L. Monoclonal immunoglobulin M λ coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
    CrossrefPubMedGoogle Scholar
  • 2 Shapiro SS, Thiagarajan P. Lupus anticoagulants. In: Progress in Hemostasis and Thrombosis Spaet T. (ed) Grune and Stratton; New York: 1982. 6 263-285
  • 3 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
    PubMedGoogle Scholar
  • 4 Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, Varma AO. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979; 91: 194-199
    CrossrefPubMedGoogle Scholar
  • 5 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
    CrossrefPubMedGoogle Scholar
  • 6 Nilsson IM, Astedt A, Hedner U, Berezin D. Intra-uterine death and circulating anticoagulant. Acta Med Scand 1975; 197: 153-159
    CrossrefPubMedGoogle Scholar
  • 7 Soulier J-P, Boffa MC. Avortements à répétition, thromboses et anticoagulant circulant anti-thromboplastine. Nouv Presse Med 1980; 9: 859-864
    PubMedGoogle Scholar
  • 8 Duran-Suarez JR, Pigrau-Serrallach C, Bosch-Gil J, Ordi-Ros J, Triginer-Boixeda J. Possible relationship between circulating anticoagulants and recurrent abortion (Letter). Haematologica 1982; 67: 320-321
    PubMedGoogle Scholar
  • 9 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In: Progress in Hemostasis and Thrombosis Spaet T. (ed) Grune and Stratton; New York: 1972. 1 75-95
  • 10 Boxer M, Ellman L, Carvalho A. The lupus anticoagulant. Arthritis Rheum 1976; 19: 1244-1248
    CrossrefPubMedGoogle Scholar
  • 11 O’Leary DS, Ruymann FB, Conrad ME. Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne). J Lab Clin Med 1971; 77: 23-32
    PubMedGoogle Scholar
  • 12 Franza R BJr, Aronson DL, Finlayson JS. Activation of human prothrombin by a procoagulant fraction from the venom of Echis carinatus. J Biol Chem 1975; 250: 7057-7067
    PubMedGoogle Scholar
  • 13 Alving CR, Shichijo S, Mattsby-Baltzer I. Preparation and use of liposomes in immunological studies. In: Liposome technology. Gre-goriadis G. (ed) CRC Press; Boca Raton: 1984: 157-175
    Google Scholar
  • 14 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
    CrossrefPubMedGoogle Scholar
  • 15 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypopro-thrombinemia-lupus anticoagulant syndrome. Blood 1983; 61: 684-692
    CrossrefPubMedGoogle Scholar
  • 16 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-816
    PubMedGoogle Scholar
  • 17 Andersson L-O, Brown JE. Interaction of factor VUI-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-167
    CrossrefPubMedGoogle Scholar
  • 18 Broden K, Brown JE, Carter C, Andersson L-O. Effect of phospholipid on factor VIII coagulant activity and coagulant antigen. Thromb Res 1983; 30: 651-660
    CrossrefPubMedGoogle Scholar
  • 19 Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 1983; 101: 34-43
    PubMedGoogle Scholar